A Phase 3 clinical trial of carbetocin nasal spray has been marked as terminated, according to a status update dated August 17, 2026. The study, registered as NCT06420297 and titled "OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome," was an open-label extension trial. It was designed to evaluate carbetocin nasal spray in people with Prader-Willi syndrome, a condition associated with hyperphagia. The trial's phase is listed as Phase 3.
The event data confirms only the status change to terminated and the associated date. No reason for termination, enrollment figures, or outcome data were included in this update. No efficacy or safety results have been reported in connection with this status change. Carbetocin remains classified as an unapproved compound under research investigation, and it has not received regulatory approval for the treatment of hyperphagia in Prader-Willi syndrome or any other indication.
Readers should note that a trial termination reflects a change in study status only. It does not by itself indicate a finding about the compound's safety or effectiveness. Further details, if released, would typically appear in subsequent updates to the trial registry entry.
For more background on this compound, see the linked compound overview.